Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients

Hemodialysis patients over 18 years were recruited after fulfilling the inclusion criteria.Seventy-one hemodialysis patients were randomized into two groups: the trial group (n =35 ) and the controls (n =36 ); a randomization numeric table was used for allocation sequence . Trial group received turmeric and control group received placebo for 12 weeks. Biochemical determinations included levels of serum albumin (Alb), potassium (K) ,blood urea nitrogen (BUN), serum creatinine (Cr), IL-6 level, TNF- α , and liver function tests and hs-CRP at the start and end of the study were measured.

Inclusion criteria

• Males or females undergoing maintenance hemodyalisis,

• Age ≥18 year
• Clinically stable and receiving adequate hemodialysis defined by a single pool Kt/V≥1.20 or no less than 3 dialysis sessions per week with a total dialysis time ≥12 hour per week for at least 3 month before enrollment,
• Diabetic patients must be willing to commence insulin therapy if deemed necessary for plasma glucose control.

Exclusion criteria

• Active malignant disease (defined as less than 5 year since receiving a diagnosis of being malignancy-free)

• Critical illness as defined by the need for respiratory or circulatory support (in an intensive care unit)
• Active vasculitis
• Severe congestive heart failure (New York Heart Association class IV)
• Severe chronic systemic infectious or inflammatory disease
• Liver disease (defined as serum alanine aminotransferase or aspartate aminotransferase levels greater than three times the upper limit of normal)
• Known or suspected allergy to trial product(s) or related products
• Treatment with immunosuppressive agents or receipt of any investigational drug within one month preceding screening
• Recent or current use of anti-inflammatory corticosteroids agents
• A scheduled renal transplantation within the trial period